Skip to main content

Table 1 Demographics, clinical features, and treatments for patients with Degos disease

From: Clinical and laboratory prognosticators of atrophic papulosis (Degos disease): a systematic review

  All Patients MAP BAP
Number of patients 105 67 38
Male/female (ratio) 47/58 (1:1.2) 35/32 (1.1:1) 12/26 (1:2.2)
Mean age of cutaneous onset (stdev) 35 (0–75) 35 (0–75) 35 (0.2–63)
Familial occurrence, n (%) 5/22 (22.7) 2/14 (14.3) 3/8 (37.5)
Mortality, n (%) N/A 48/67 (71.6%) N/A
Mean follow up time of study 2.55 (3.01) 2.20 (2.69) 3.36 (3.53)
Distribution of lesions, n (%)    
 Generalized 95/104 (91.3) 61/66 (92.4) 34/38 (89.5)
 Localized 9/104 (8.7) 5/66 (7.6) 4/38 (10.5)
Primary or secondary Degos, n (%)
 Primary 94/105 (89.5) 63/67 (94) 31/38 (81.6)
 Secondary 11/105 (10.5) 4/67 (6.0) 7/38 (18.4)
 Dermatomyositis 2/105 (1.9) 0/67 (0) 2/38 (5.3)
 Relapsing polychondritis 1/105 (1) 0/67 (0) 1/38 (2.6)
 Rheumatoid arthritis 1/105 (1) 1/67 (1.5) 0/38 (0)
 Systemic lupus erythematosus 8/105 (7.6) 2/67 (3) 6/38 (15.8)
Treatments, n (%)
 Anticoagulant 20/93 (21.5) 19/63 (30.2) 1/30 (3.3)
 Antiplatelet (Single) 29/93 (31.2) 21/63 (33.3) 8/30 (26.7)
 Antiplatelet (Dual) 19/93 (20.4) 14/63 (22.2) 5/30 (16.7)
Biologics
 Eculizumab 8/93 (8.6) 8/63 (12.7) 0/30 (0)
 Infliximab 3/93 (3.2) 3/63 (4.8) 0/30 (0)
 Natalizumab 1/93 (1.1) 1/63 (1.6) 0/30 (0)
 Rituximab 2/93 (2.2) 2/63 (3.17) 0/30 (0)
 Corticosteroids (topical and oral) 39/93 (41.2) 31/63 (49.2) 8/30 (26.7)
Immunomodulators
 Aminosalicylates 1/93 (1.1) 1/63 (1.6) 0/30 (0)
 Azathioprine 2/93 (2.2) 1/63 (1.6) 1/30 (3.3)
 Cyclosporin A 3/93 (3.2) 2/63 (3.2) 1/30 (3.3)
 IVIg 13/93 (14) 11/63 (17.5) 2/30 (6.6)
 Methotrexate 4/93 (4.3) 2/63 (3.2) 2/30 (6.6)
 Tacrolimus 2/93 (2.2) 1/63 (1.6) 1/30 (3.3)
 Thalidomide 1/93 (1.1) 1/63 (1.6) 0/30 (0)
 Prostaglandin 2/93 (2.2) 1/63 (1.6) 1/30 (3.3)
Steroid sparing agents
 Cyclosporine 2/93 (2.2) 2/63 (3.2) 0/30 (0)
 Dapsone 2/93 (2.2) 1/63 (1.6) 1/30 (3.3)
Others
 Cyclophosphamide 7/93 (7.5) 7/63 (11.1) 0/30 (0)
 Pentoxifylline 9/93 (9.7) 6/63 (9.52) 3/30 (10)
 No Treatment 7/93 (7.5) 1/63 (1.6) 6/30 (20)
 Not Reported 12/93 (12.9) 4/63 (6.4) 8/30 (26.7)
Abnormal labs, n (%)
 ESR/CRP 14/76 (18.4) 13/48 (27.1) 1/28 (3.6)
 ANA 10/75 (13.3) 4/46 (8.7) 6/29 (20.1)
Patient geographic distribution, n (%)
 Asia 33/105 (31.4) 23/67 (34.3) 10/38 (26.3)
 North America 28/105 (26.7) 17/67 (25.4) 11/38 (28.9)
 South America 2/105 (1.9) 2/67 (3) 0/38 (0)
 Europe 38/105 (36.2) 22/67 (32.8) 16/38 (42.1)
 Africa 0/105 (0) 0/67 (0) 0/38 (0)
 Australia 4/105 (3.8) 3/67 (4.5) 1/38 (2.6)
  1. MAP, malignant atrophic papulosis; BAP, benign atrophic papulosis; N/A, not applicable